The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of trametinib in combination with paclitaxel in the treatment of anaplastic thyroid cancer.
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron (Inst)
 
Loren S. Michel
Research Funding - Exelixis (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Anuja Kriplani
No Relationships to Disclose
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
Deborah Bang
No Relationships to Disclose
 
Sarah Stein
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Incyte
Research Funding - AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Alan Loh Ho
Consulting or Advisory Role - AffyImmune Therapeutics; AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Cellestia Biotech; CureVac; CureVac; Eisai; Eisai; Exelixis; Genzyme; InxMed; Kura Oncology; McGivney Global Advisors; Merck; Novartis; Prelude Therapeutics; Regeneron; Rgenta; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck